Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCorRx Inc.BICX · Entity 8179 | Director · President · 10% owner | April 24, 2024 | January 31, 2025 |
| RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.OPP · Entity 6374 | Exec Comm Mbr: OPP Subadviser | September 27, 2016 | September 27, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCorRx Inc.
Report date April 24, 2024 · Filed January 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 2,511,940 |
Ending reported balance
After 2024-12-31 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2024-04-24 · Other · Acquired 460,477 · Balance 1,083,293 F1: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 24, 2024 (the "April 2024 Exchange Agreement"). Pursuant to the April 2024 Exchange Agreement, Mr. Lucido agreed to the exchange of a promissory note then outstanding in the amount of $446,426 and the accrued interest on such promissory note of $7,858 and director fees of $90,000 for 460,477 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance. Row 2 · 2024-07-31 · Grant · Acquired 32,092 · Balance 1,115,385 F2: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.5193. Row 3 · 2024-08-30 · Grant · Acquired 55,559 · Balance 1,170,944 F3: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30. Row 4 · 2024-09-30 · Grant · Acquired 52,085 · Balance 1,223,029 F4: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Row 5 · 2024-09-30 · Grant · Acquired 15,625 · Balance 1,238,654 F5: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019 (the "Director Agreement"), by and between the Company and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Row 6 · 2024-10-14 · Grant · Acquired 1,105,218 · Balance 2,343,872 F6: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated October 14, 2024 (the "October 2024 Exchange Agreement"). Pursuant to the October 2024 Exchange Agreement, Mr. Lucido agreed to the exchange the aggregate amount of $387,6700 of director's fees and loans to a subsidiary of the Company for 1,105,218 shares of Common Stock at a price of $0.36 per share based on the underlying value of the Common Stock at the date of issuance. Row 7 · 2024-10-31 · Grant · Acquired 55,556 · Balance 2,399,428 F7: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30. Row 8 · 2024-11-29 · Grant · Acquired 55,494 · Balance 2,454,922 F8: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.31. Row 9 · 2024-12-31 · Grant · Acquired 43,860 · Balance 2,498,782 F9: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. Row 10 · 2024-12-31 · Grant · Acquired 13,158 · Balance 2,511,940 F10: These shares were issued to Mr. Lucido pursuant to the Director Agreement. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 24, 2024 (the "April 2024 Exchange Agreement"). Pursuant to the April 2024 Exchange Agreement, Mr. Lucido agreed to the exchange of a promissory note then outstanding in the amount of $446,426 and the accrued interest on such promissory note of $7,858 and director fees of $90,000 for 460,477 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance.
F2: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.5193.
F3: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30.
F4: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.
F5: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019 (the "Director Agreement"), by and between the Company and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32.
F6: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated October 14, 2024 (the "October 2024 Exchange Agreement"). Pursuant to the October 2024 Exchange Agreement, Mr. Lucido agreed to the exchange the aggregate amount of $387,6700 of director's fees and loans to a subsidiary of the Company for 1,105,218 shares of Common Stock at a price of $0.36 per share based on the underlying value of the Common Stock at the date of issuance.
F7: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30.
F8: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.31.
F9: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.
F10: These shares were issued to Mr. Lucido pursuant to the Director Agreement. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38.
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.
Report date September 27, 2016 · Filed September 27, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2016-09-27 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 13,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 10 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,511,940 F10 · kind: These shares were issued to Mr. Lucido pursuant to the Director Agreement. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. Read SEC document |
| December 31, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 43,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 9 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,498,782 F9 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. Read SEC document |
| November 29, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 55,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 8 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,454,922 F8 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.31. Read SEC document |
| October 31, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 55,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 7 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,399,428 F7 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30. Read SEC document |
| October 14, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,105,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 6 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,343,872 F6 · kind: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated October 14, 2024 (the "October 2024 Exchange Agreement"). Pursuant to the October 2024 Exchange Agreement, Mr. Lucido agreed to the exchange the aggregate amount of $387,6700 of director's fees and loans to a subsidiary of the Company for 1,105,218 shares of Common Stock at a price of $0.36 per share based on the underlying value of the Common Stock at the date of issuance. Read SEC document |
| September 30, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 5 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,238,654 F5 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019 (the "Director Agreement"), by and between the Company and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Read SEC document |
| September 30, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 52,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 4 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,223,029 F4 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. Read SEC document |
| August 30, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 55,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,170,944 F3 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.30. Read SEC document |
| July 31, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 32,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,115,385 F2 · kind: These shares were issued to Mr. Lucido pursuant the Service Agreement. As compensation for his services under the Service Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Service Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.5193. Read SEC document |
| June 28, 2024 Filed Jul 10, 2024 17:02 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 34,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-004156 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 622,816 F2 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49. Read SEC document |
| June 28, 2024 Filed Jul 10, 2024 17:02 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 10,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-004156 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,800 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. (the "Company") and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock par value $0.001 per share (the "Common Stock") equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 01:44 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 22,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003436 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,596 F1 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.73. Read SEC document |
| April 30, 2024 Filed May 2, 2024 00:17 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 21,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-002476 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,765 F1 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.77. Read SEC document |
| April 24, 2024 Filed Jan 31, 2025 16:19 UTC | BioCorRx Inc. BICX · Entity 8179 | OtherCommon Stock, par value $0.001 | 460,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000598 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083,293 F1 · kind: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 24, 2024 (the "April 2024 Exchange Agreement"). Pursuant to the April 2024 Exchange Agreement, Mr. Lucido agreed to the exchange of a promissory note then outstanding in the amount of $446,426 and the accrued interest on such promissory note of $7,858 and director fees of $90,000 for 460,477 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance. Read SEC document |
| March 28, 2024 Filed Apr 3, 2024 13:00 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 18,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-001820 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,213 F2 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90. Read SEC document |
| March 28, 2024 Filed Apr 3, 2024 13:00 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 5,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-001820 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,660 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. (the "Company") and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock par value $0.001 per share (the "Common Stock") equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90. Read SEC document |
| February 29, 2024 Filed Mar 8, 2024 00:42 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 16,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-001093 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,094 F2 · kind: These shares were issued to Mr. Lucido pursuant to the Agreement. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares of Common Stock equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.98. Read SEC document |
| January 31, 2024 Filed Mar 8, 2024 00:42 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 18,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-001093 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,202 F1 · kind: These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between BioCorRx Inc. (the "Company") and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), equivalent to $16,666.66 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.80. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 126 | $0.70 | $88.20 |
DisclosureSEC source: 0001477932-24-000249 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · Interim President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,933 Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 3,000 | $0.70 | $2,100.00 |
DisclosureSEC source: 0001477932-24-000249 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · Interim President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,807 Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 20:47 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000037 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,807 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 20:50 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-007296 · primary_doc.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,634 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:03 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005017 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,776 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:15 UTC | BioCorRx Inc. BICX · Entity 8179 | OtherCommon Stock, par value $0.001 | 183,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002273 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,885 F2 · kind: These shares were issued to Mr. Lucido pursuant to an exchange agreement by and between BioCorRx Inc. (the "Company") and Mr. Lucido dated April 3, 2023 (the "Exchange Agreement"). Pursuant to the Exchange Agreement, the Company agreed to issue 183,606 shares of its common stock, par value $0.001 per share, to Mr. Lucido and Mr. Lucido agreed to exchange, surrender and cancel that certain promissory note dated November 1, 2022 held by Mr. Lucido in the aggregate amount of $313,892, including interest. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 171,296 | $1.75 | $299,768.00 |
DisclosureSEC source: 0001477932-23-002273 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 276,279 F1 · kind: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017, managed by Mr. Louis C Lucido (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated March 29 2023, and paid for on April 3, 2023. The Reporting Person may be deemed to have investment power over the Lucido Trust. F1 · ownership.nature: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017, managed by Mr. Louis C Lucido (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated March 29 2023, and paid for on April 3, 2023. The Reporting Person may be deemed to have investment power over the Lucido Trust. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:29 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-002226 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,983 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 100 | $1.37 | $137.00 |
DisclosureSEC source: 0001477932-23-000644 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,159 Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 300 | $1.39 | $417.00 |
DisclosureSEC source: 0001477932-23-000644 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,059 Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 500 | $1.29 | $646.50 |
DisclosureSEC source: 0001477932-23-000587 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,759 Read SEC document |
| January 24, 2023 Filed Jan 25, 2023 19:32 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 200 | $1.20 | $240.00 |
DisclosureSEC source: 0001477932-23-000530 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,259 Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 2,000 | $1.15 | $2,300.00 |
DisclosureSEC source: 0001477932-23-000335 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,059 Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 21:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 2,000 | $1.10 | $2,200.00 |
DisclosureSEC source: 0001477932-23-000335 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,059 Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:16 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 2,000 | $1.10 | $2,200.00 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 4 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,059 Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:16 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,059 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94 Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:16 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 115 | $1.03 | $118.45 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,740 Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:16 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 200 | $0.98 | $195.00 |
DisclosureSEC source: 0001477932-23-000088 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,625 Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 2,000 | $0.80 | $1,600.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 4 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,425 Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 1,000 | $0.80 | $800.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,425 Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 1,000 | $0.98 | $980.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,425 Read SEC document |
| December 12, 2022 Filed Dec 15, 2022 12:29 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 1,000 | $0.79 | $790.00 |
DisclosureSEC source: 0001477932-22-009312 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,425 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:59 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 100 | $1.73 | $173.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 5 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,425 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:59 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 120 | $1.90 | $228.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 4 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,325 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:59 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 360 | $1.90 | $684.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,205 Read SEC document |
| October 05, 2022 Filed Oct 11, 2022 21:59 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 1,000 | $2.02 | $2,020.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,845 Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 20:08 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007471 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,835 F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| September 06, 2022 Filed Oct 11, 2022 21:59 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 10 | $2.10 | $21.00 |
DisclosureSEC source: 0001477932-22-007543 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,845 Read SEC document |
| August 31, 2022 Filed Aug 31, 2022 23:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 610 | $2.12 | $1,293.20 |
DisclosureSEC source: 0001477932-22-006572 · form4.xml · nonDerivative · entry 3 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,385 Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 23:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 2,268 | $2.10 | $4,762.80 |
DisclosureSEC source: 0001477932-22-006572 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,775 Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 23:15 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 1,000 | $2.12 | $2,120.00 |
DisclosureSEC source: 0001477932-22-006572 · form4.xml · nonDerivative · entry 1 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,507 Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 16:16 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 560 | $2.12 | $1,187.20 |
DisclosureSEC source: 0001477932-22-006484 · form4.xml · nonDerivative · entry 2 Lucido Louis C. · CIK 0001539788 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,507 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.